Genor Biopharma Holdings Limited ( (HK:6998) ) has issued an update.
Genor Biopharma Holdings Limited has announced an extraordinary general meeting to address the removal of PricewaterhouseCoopers as its auditor, replacing them with Ernst & Young. This strategic decision may impact the company’s financial oversight and potential stakeholder confidence, reflecting a significant shift in their operational approach.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a company incorporated in the Cayman Islands, operating within the biopharmaceutical industry. It focuses on developing and manufacturing a range of pharmaceutical products, particularly in the area of biologics, with a market focus on China and potentially wider Asian markets.
YTD Price Performance: 12.63%
Average Trading Volume: 20,382
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €122.1M
For a thorough assessment of 6998 stock, go to TipRanks’ Stock Analysis page.